Mendus announces clinical pipeline update
GlobeNewswire
*Press Release*
Stockholm, Sweden, December 22, 2023
Mendus AB (“Mendus” publ; IMMU.ST), a..
High-grade serous carcinoma
News and Video Search Results
News coverage
-
Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy
GlobeNewswire
-
Previously Unidentified Proteins Suggest New Way To Diagnose Ovarian Cancer
Eurasia Review
-
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
GlobeNewswire
-
Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept
GlobeNewswire
- More about:
Japan
0 shares
1 views
You might like
High-grade serous carcinoma media coverage
Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
GlobeNewswire
Company on Track for PROC Phase 3, Pivotal Trial Readout in Mid 2023; Ends Year with Strengthened Cash Position
HOUSTON,..
-
Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
GlobeNewswire
-
Aravive Receives Third Development Milestone from 3D Medicines
GlobeNewswire
-
Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation
GlobeNewswire
-
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
GlobeNewswire
Advertisement
More coverage
Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors
ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumorsZN-c3 was..
GlobeNewswire
Prelude Therapeutics Announces Third Quarter 2020 Financial Results
- Completed Initial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M -- Partial Response Confirmed in..
GlobeNewswire